The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma

  • Authors:
    • Lucio Tentori
    • Annalisa Susanna Dorio
    • Alessia Muzi
    • Pedro Miguel Lacal
    • Federica Ruffini
    • Pierluigi Navarra
    • Grazia Graziani
  • View Affiliations

  • Published online on: April 1, 2008     https://doi.org/10.3892/or.19.4.1039
  • Pages: 1039-1043
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Inhibitors of αv integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists. In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma. To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy.

Related Articles

Journal Cover

April 2008
Volume 19 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P and Graziani G: The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19: 1039-1043, 2008
APA
Tentori, L., Dorio, A.S., Muzi, A., Lacal, P.M., Ruffini, F., Navarra, P., & Graziani, G. (2008). The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncology Reports, 19, 1039-1043. https://doi.org/10.3892/or.19.4.1039
MLA
Tentori, L., Dorio, A. S., Muzi, A., Lacal, P. M., Ruffini, F., Navarra, P., Graziani, G."The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma". Oncology Reports 19.4 (2008): 1039-1043.
Chicago
Tentori, L., Dorio, A. S., Muzi, A., Lacal, P. M., Ruffini, F., Navarra, P., Graziani, G."The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma". Oncology Reports 19, no. 4 (2008): 1039-1043. https://doi.org/10.3892/or.19.4.1039